Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Phio Pharmaceuticals Corp. (PHIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6550-0.0030 (-0.46%)
At close: 04:00PM EDT
0.6560 +0.00 (+0.15%)
After hours: 07:48PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close0.6580
Open0.6649
Bid0.6522 x 1000
Ask0.6630 x 1400
Day's Range0.6400 - 0.7400
52 Week Range0.6200 - 2.4700
Volume1,601,824
Avg. Volume3,640,539
Market Cap8.946M
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PHIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Phio Pharmaceuticals Corp.
    Analyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
    Rating
    Fair Value
    Economic Moat
    9 days agoMorningstar
View more
Advertisement
Advertisement